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Background. Patients with type 1 diabetes are at markedly increased risk for vascular
complications. In this respect it is noteworthy that hyperglycaemia, shown to cause endothelial
dysfunction, has clearly been shown to be a risk factor for diabetic microvascular disease. The role
of hyperglycaemia as a predictor of macrovascular disease is, however, not as clear as for
microvascular disease, although type 1 diabetes itself elevates risk for cardiovascular disease
substantially. Furthermore, what is unknown is whether the short-term or the long-term
hyperglycaemia confers the possible risk. In addition, the role of glucose variability as a predictor
of complications is to a large extent unexplored. Interestingly, although hyperglycaemia elevates
risk  for  pre-eclampsia  in  women  with  type  1  diabetes,  it  is  unclear  whether  pre-eclampsia,  a
condition characterized by endothelial dysfunction, is also a risk factor for microvascular
complication, diabetic nephropathy.
Aims. This doctoral thesis investigates the role of acute hyperglycaemia and glucose variability on
arterial stiffness and cardiac ventricular repolarisation in male patients with type 1 diabetes as well
as in healthy male volunteers. It also explores whether acute hyperglycaemia leads to an
inflammatory response, endothelial dysfunction, and oxidative stress. Finally, the role of pre-
eclampsia, as a predictor of diabetic nephropathy in type 1 diabetes is examined.
Subjects and methods. In  order  to  study  glucose  variability  and  daily  glycaemic  control,  22  male
patients with type 1 diabetes, but without any diabetic complications, were monitored for 72 h with
a continuous glucose monitoring system. At the end of the 72 h glucose monitoring period a 2 h
hyperglycaemic clamp was performed both in the patients with type 1 diabetes and in the 13 healthy
age-matched male volunteers. Blood pressure, arterial stiffness, and QT time were measured to
detect vascular changes during acute hyperglycaemia. Blood samples were drawn at baseline
(normoglycaemia) and during acute hyperglycaemia. In another patient sample, women with type 1
diabetes were followed during their pregnancy and restudied 11 years later to elucidate the role of
pre-eclampsia and pregnancy-induced hypertension as potential risk factors for diabetic
nephropathy.
Results and conclusions.  Acute hyperglycaemia increased arterial stiffness as well as caused a
disturbance in the myocardial ventricular repolarisation, emphasizing the importance of strict daily
glycaemic control in male patients with type 1 diabetes. An inflammatory response was also
observable during acute hyperglycaemia. Furthermore, high mean daily blood glucose but not
glucose variability per se is associated with arterial stiffness. While glucose variability in turn
correlated with central blood pressure, the results suggest that the glucose metabolism is closely
linked to the haemodynamic changes in male patients with uncomplicated type 1 diabetes. Notably,
these results are not directly applicable to females. Finally, a history of a pre-eclamptic pregnancy,
but not pregnancy-induced hypertension was associated with increased risk for diabetic
nephropathy.
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1 Introduction
The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective
Diabetes Study (UKPDS) demonstrated that tight glycaemic control is important in order to prevent
diabetic microvascular complications 1 2. Conversely, chronic hyperglycaemia has not
unequivocally been proven to be a risk factor for macrovascular complications 3, although diabetes
itself leads to increase risk for cardiovascular disease 4 5.
The possible role played by acute change in glycaemic control as a risk factor for diabetic
complications is poorly understood. It is, however, noteworthy that acute hyperglycaemia seems to
be a risk factor for worse prognosis during acute cardiovascular events in patients with and without
diabetes 6. Postprandial hyperglycaemia is, in turn, a risk factor for cardiovascular disease in
patients with type 2 diabetes 7. Acute hyperglycaemia is also suggested to cause vascular changes in
non-diabetic subjects 8. Nevertheless, whether acute hyperglycaemia affects the vasculature in
patients with type 1 diabetes is largely unknown.
Surprisingly, despite the fact that patients with type 1 diabetes are known to show marked glucose
fluctuations on a daily basis, glucose variability in relation to diabetic complications is a less
studied subject in vivo. A recent study has, however, shown that glucose variability is a risk factor
for patients in intensive care 9.  In  contrast,  a  few  recent  studies  have  suggested  that  glucose
variability does not predict diabetic complications 10 11. Any potential association between glucose
variability and macrovascular disease in patients with type 1 diabetes is incompletely explored.
Intermediate markers are widely used in patients with diabetes to predict complications. Arterial
stiffness is one such factor with important clinical consequences and may serve as an intermediate
marker for cardiovascular disease. Furthermore, heart rate-corrected QT time (QTc) is a measure of
cardiac ventricular repolarisation. A prolonged QTc is an established risk factor for cardiac sudden
death and hence suitable as an intermediate marker for macrovascular complications  12.
Chronically elevated blood glucose concentrations are thought to cause diabetic complications
through a number of different mechanisms such as chronic inflammation, endothelial dysfunction,
and oxidative stress, and these features have also been linked to both micro- and macrovascular
complications 13. However, it is unclear whether acute hyperglycaemia also leads to an
inflammatory response, endothelial dysfunction, and oxidative stress and subsequent vascular
changes in patients with type 1 diabetes, although for patients with type 2 diabetes such data exist
14.
Pre-eclampsia is a serious condition that affects a proportion of pregnant women. It is characterized
by endothelial dysfunction, hypertension, and massive proteinuria. Hyperglycaemia is a risk factor
for pre-eclampsia, and the incidence of the disorder is markedly increased in patients with type 1
diabetes 15. Diabetic nephropathy is, in turn, a serious microvascular complication of diabetes.
Although pre-eclampsia and nephropathy have many common pathogenic factors, no studies have
10
elucidated whether pre-eclampsia is a predictor of diabetic nephropathy in patients with type 1
diabetes.
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2 Review of the literature
2.1 Type 1 diabetes
An estimated 246 million people worldwide have diabetes 16. Among all patients suffering from this
disease, type 1 diabetes accounts for 5 to 10% 17. The incidence is for mostly unknown reasons the
highest in the world in Finland 18, and the condition substantially influences patients’ daily life and
prognosis 19. Type 1 diabetes is caused by an autoimmune destruction of the insulin-producing
pancreatic beta-cells that eventually leads to a total loss of insulin secretion. The disease usually
emerges acutely and is characterized by hyperglycaemia, ketoacidosis, polyuria, weight loss and
dehydration. A life-saving treatment was discovered in the 1920’s by Banting and Best when they
developed insulin therapy 20.
The etiology of type 1 diabetes is thought to involve both genetic and environmental factors. The
genetic component is supported by the observation that the concordance rate of the disease varies
from  20%  to  at  least  50%  for  monozygotic  twins,  while  the  risk  for  a  first-degree  relative  is
approximately 5% 21 22 23. An important genetic determinant that affects susceptibility lies within
the major histocompatibility complex, although other locations are also intensively studied 24.
Although there is no doubt that environmental factors contribute to the development of type 1
diabetes, their true role in its pathogenesis is still a matter of debate. There exist, however, a few
plausible hypotheses. Firstly, a viral component is proposed by the fact that the incidence is higher
during certain periods of the year 25. Secondly, some data suggest that the intake of bovine milk at
an early age or even vaccinations might contribute to the risk, although these theories have also
been challenged 26. Thirdly, some results indicate that the environment in the western world may be
too sterile and may thus lead to a weakening of the immunological mechanisms 27.
2.2 Long-term complications in type 1 diabetes
Long-term complications of diabetes are categorized into micro- and macrovascular disease.
Diabetic microvascular complications consist of diabetic nephropathy, retinopathy, and neuropathy.




An important risk factor for the development of diabetic microvascular disease is hyperglycaemia, a
fact that has been shown in many large studies 1 28 29 30. Other risk factors also emerge, however,
such as hypertension, smoking, dyslipidaemia, duration of diabetes, and genetic susceptibility 31 32.
2.2.1.1 Diabetic nephropathy
Diabetic nephropathy is characterized by an increase in urinary albumin excretion rate (AER),
elevated blood pressure, a relentless decline in renal function, endothelial dysfunction, and a 37-fold
increased risk for cardiovascular mortality 33.  Patients  with  diabetic  nephropathy  compared  to
patients without have a more than 10-fold increased risk for developing cardiovascular disease 34.
Approximately one third of patients with type 1 diabetes will develop diabetic nephropathy, but
recent data indicate that the proportion may be lower due to successful treatment of hyperglycaemia
and hypertension 35 36. Poor glycaemic control, smoking, male gender, hypertension, and
predisposing genes are risk factors for nephropathy in these patients 37 38 39. Importantly, several
detectable steps help the clinician make the diagnosis of diabetic nephropathy, because
development of this renal complication goes through various stages, from microalbuminuria
(defined as AER between 20 <200 µg/min or 30 <300 mg/24h), to overt nephropathy or
macroalbuminuria (AER 200 µg/min or 300 mg/24h ) and finally leads to end-stage renal
disease. Given the grim statistics regarding the prognosis of patients with diabetic nephropathy,
efficient screening for microalbuminuria is a cornerstone of the management of patients with type 1
diabetes. Patients should therefore be screened for microalbuminuria annually starting 5 years after
the diagnosis of type 1 diabetes.
The importance of strict glycaemic control cannot be overemphasized for the treatment of type 1
diabetes as a means to avoid complications. However, at the stage of advanced diabetic
nephropathy, the role and efficacy of strict glycaemic control is less clear. In contrast, angiotensin-
converting enzyme inhibitors and angiotensin receptor-blocking agents are drugs of choice not only
to lower blood pressure but also to protect the kidneys at all stages of diabetic nephropathy. Lipid
control  and  cessation  of  smoking  are  also  of  importance,  alongside  the  administration  of
renoprotective agents 40. Notably, the treatment is not only essential to protect the kidneys from
damage but also essential because microalbuminuria is an independent predictor of cardiovascular
disease 41.
2.2.1.2 Diabetic retinopathy
Diabetic retinopathy is an important microvascular complication in diabetes in the western world
and a major cause of blindness 42. The natural cause or the progression of the complication can be
divided into a number of clinically detectable stages. It starts with non-proliferative changes
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(microaneurysms, exudates, haemorrhages), and advances to preproliferative retinopathy,
proliferative retinopathy, and macular oedema.
After 20 years of diabetes almost all patients with type 1 diabetes show signs of retinopathy. Most
of the patients have background retinopathy, a complication that seldom leads to severe vision loss.
However, when retinopathy worsens, severe visual loss eventually threatens 5 to 10% 43. The most
severe form of retinopathy is proliferative retinopathy and most with this complication will become
blind after 5 to 10 years without treatment 44.  After  15  to 20 years of diabetes the prevalence of
proliferative retinopathy ranges from 13 to 50%45.
Hyperglycaemia, hypertension, microalbuminuria, dyslipidaemia, and duration of diabetes are all
risk factors for diabetic retinopathy 46 47. Notably, a strong correlation emerges between diabetic
nephropathy and proliferative retinopathy 48. All patients with type 1 diabetes should undergo
regular screening to detect retinopathy. The prevention and treatment of diabetic retinopathy
includes strict glycaemic control, antihypertensive treatment, and lipid control; laser therapy is an
effective means to avoid blindness 49.
2.2.1.3 Diabetic neuropathy
Diabetic neuropathy is a common long-term complication of diabetes, affecting some 50% of
patients 50. It can be divided into two major forms: generalized and focal 51. A common form of
generalized neuropathy is peripheral sensorimotor polyneuropathy. Peripheral polyneuropathy
together with a poor peripheral arterial circulation often results in problems with wound healing,
gangrene and in the worst case, limb amputation. The generalized diabetic neuropathy also includes
autonomic neuropathy, seen often as cardiac dysfunction, exercise intolerance, gastroparesis, or
erectile dysfunction. Typical focal neuropathies include carpal tunnel syndrome, diabetic
amyotrophy, and nerve palsies 52.
Physicians need to screen for neuropathy starting 5 years after the diagnosis of diabetes, and this
screening should be carried out on a regular basis with appropriate methods. Again, tight glycaemic
control is the key player in the prevention and management of diabetic neuropathy 53. Tricyclic
agents are used to treat painful neuropathy, and anticonvulsants or even opioids are the choice in
some cases to manage severe pain that does not respond to other treatment 54.
2.2.2 Macrovascular disease
Type 1 diabetes elevates the risk for atherosclerosis and macrovascular disease substantially but
despite the fact that these complications are rather common, the pathogenesis is still poorly
understood. Risk for cardiovascular disease has been more than 10-fold higher in patients with
diabetic nephropathy 34, but even patients without nephropathy still are at increased risk 55 56 57. The
classic risk factors for atherosclerosis such as smoking, high blood pressure, dyslipidaemia, age,
and impaired glucose tolerance seem to be operative also in this patient group, although they cannot
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alone explain the increased risk. Hyperglycaemia would be a plausible factor to serve as the logical
missing link, but it has, however, not unequivocally been shown to be a risk factor for
macrovascular complications 3 58 59.
Recent data from the DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC)
study showed that intensive insulin therapy with subsequent tight glycaemic control reduces risk for
cardiovascular disease in patients with type 1 diabetes 60. It is, however, of note that only 83 of the
1441 patients studied suffered cardiovascular events. Moreover, the EDIC reported a lower rate of
progression of carotid intima-media thickening and reduced coronary artery calcification as
surrogate markers of cerebrovascular and cardiovascular disease in the patient group with better
glycaemic control 61 62. Similar results are also available regarding peripheral arterial disease 63.
Interestingly,  the  Pittsburgh  Epidemiology  of  Diabetes  Complications  Study  (EDC)  reported  a
stronger correlation between glycaemia and cardiovascular disease in patients with
normoalbuminuria than in patients with diabetic nephropathy 64.  In  addition,  results  from  the
EURODIAB Study showed that HbA1c was related to coronary heart disease in men but not in
women with type 1 diabetes 65.
Regarding the role of chronic hyperglycaemia as a risk factor for cardiovascular disease in patients
with type 2 diabetes, data are conflicting. The UKPDS did not exhibit a reduction in cardiovascular
events in patients with type 2 diabetes, although a subgroup of patients treated with metformin had
a lower risk for such events 66. Intriguingly, two large trials, the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial  and the Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, failed to demonstrate any
effect on cardiovascular risk in patients with type 2 diabetes from lowering glucose to near-normal
levels 67 68. In fact, the near-normal glucose control in the ACCORD trial was associated with
significantly increased risk of death from any cause and death from cardiovascular disease.
Although the data are still somewhat conflicting, glucose control is suggested to be important in
preventing not only microvascular but also macrovascular disease 60. Moreover, the
recommendations for lipid control are even more strict for patients with type 1 diabetes than for the
non-diabetic population 69 70. Strict control of blood pressure (<130/80 mmHg) is also
recommended by the American Diabetes Association (ADA) and the European Association for the
Study of Diabetes (EASD) 71 72. The drugs of choice for patients with diabetes are either
angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor-blocking (ARB) agents.
However, the antihypertensive medication should always be individually tailored for the patient,
and other possible diseases (for example beta-blockers in cases of coronary heart disease) should
also be taken into account. Aspirin therapy should be initiated for all patients with type 1 diabetes
>40 years of age or who have at least one cardiovascular disease risk factor 70.  Cessation  of
smoking is of outmost importance for the prevention of cardiovascular disease 73.
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2.3 Hyperglycaemia
The blood glucose concentration in a non-diabetic individual is strictly controlled by the interplay
between a number of hormones, physiological insulin secretion from the pancreas, and insulin
action in the target organ, as well as glucagon, catecholamines, cortisone, growth hormones, and
prolactin. As the insulin secretion fails in patients with type 1 diabetes, insulin has to be
administered exogenously for the patient to stay alive. However, modern insulin regimens aim not
only to compensate for the insulin depletion but also to optimize glycaemic control and to minimize
the blood glucose variability.
2.3.1 Acute hyperglycaemia
Blood glucose is usually measured by the patients themselves by self-monitoring blood glucose
(SMBG) devices. The recommendations suggest three or more SMBG measures daily to achieve
better glycaemic control 70. Blood glucose can also be measured by a continuous glucose
monitoring system (CGMS). Acute hyperglycaemia can lead to polyuria, dehydration, and ketosis,
whereas acute hypoglycaemia can lead to cold sweating, tachycardia, and if severe even to loss of
consciousness.
Acute hyperglycaemia is associated with increased acute cardiovascular mortality, whether the
patient  has  diabetes  or  not 6. Moreover, evidence exists that patients with hyperglycaemia during
severe stress such as traumas have a worse prognosis than normoglycaemic patients 74.
The effect of acute hyperglycaemia on the cardiovascular system is not completely known.
However, acute hyperglycaemia has been demonstrated to cause arrhythmias in patients with acute
myocardial infarction (AMI) 75. This is in line with another important finding that an acutely
increased blood glucose concentration will prolong the QT time in healthy volunteers 76. This
observation has been repeated in a rat model 77. In addition, acutely increased blood glucose
concentrations are associated with impaired left ventricular function, and a larger size infarction in
patients with an AMI 78 79. Importantly, Mullan et al. reported significant arterial stiffening during
acute hyperglycaemia in healthy males 8. Such data may explain the enhanced mortality in
association with an AMI in patients with acute hyperglycaemia.
As to changes in haemostasis, evidence suggests an activation of the blood coagulation system
during acute hyperglycaemia 80. It is noteworthy that Oswald et al. some 20 years ago, had already
showed an association between thrombophilia and hyperglycaemia in non-diabetic patients with an
AMI 81. Taken together, all these findings may explain the increased risk of mortality during acute
cardiovascular events in patients with high blood glucose concentrations.
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2.3.1.1 Inflammation
Chronic inflammation has during recent years been linked to cardiovascular disease: atherosclerosis
and acute coronary syndromes 82 83. Some data also link worse cardiac outcome and inflammatory
markers in patients with AMI 84. Moreover, highly sensitive C-reactive protein (CRP), and
interleukin-6 (Il-6) independently predict the outcome of patients with coronary heart disease in the
general population 85 86. Ceriello and his colleagues have shown that acute hyperglycaemia
enhances the production of inflammatory markers in healthy subjects, in patients with impaired
glucose tolerance, and in patients with type 2 diabetes 87 88 89. Whether an acute rise in blood
glucose triggers an inflammatory response in patients with type 1 diabetes is not known
2.3.1.2 Endothelial function
The endothelium is the organ forming the inner layer of the vasculature, and given its widespread
distribution all over the body and its multi-faceted secretion of vasoactive substances, it is also
considered the largest endocrine organ. The endothelium has a number of vital functions. Its
morphology and function differ throughout the vasculature. It participates in thrombolysis, platelet
adhesion, inflammatory processes, and substrate exchange, as well as in the regulation of vascular
tone and growth 139.
It has also been shown to be involved in the pathogenesis of vascular disease. Several studies have
consistently reported impaired endothelial function as a consequence of an increased blood glucose
concentration 90 91 92. Endothelial dysfunction is also thought to be involved in the formation of
atherosclerotic plaques 93, and therefore, not surprisingly, is associated not only with AMI 94 but
also with chronic inflammation 95. Interestingly, a recent study suggested that in patients with type 1
diabetes a synchronous control of oxidative stress and hyperglycaemia normalizes the endothelial
function 96.
2.3.1.3 Oxidative stress
Mitochondrial superoxide overproduction leads to tissue damage through reactive oxygen species.
Oxidative stress is a well-known pathogenic factor for both atherosclerosis and cardiovascular
disease 97. Nitrotyrosine, a marker of oxidative stress, has been an independent predictor of
cardiovascular disease 98. It is noteworthy that acute hyperglycaemia has been linked to oxidative
stress 99 not only in experimental animals but also in healthy subjects and patients with type 2
diabetes 100 101 102.   An  acutely  elevated  blood  glucose  concentration  has  recently  been  shown  to
downregulate gene expression in adipose tissue and skeletal muscle in healthy subjects 103. Finally,
antioxidants can reduce the adverse effects of acute hyperglycaemia on endothelial dysfunction and
inflammation 104.
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2.3.1.4 Treatment of acute hyperglycaemia
The increased cardiovascular mortality in patients with acute hyperglycaemia argues for tight blood
glucose control during an acute cardiovascular event. The Diabetes and Insulin-Glucose Infusion in
Acute Myocardial Infarction (DIGAMI) I study demonstrated that an insulin-glucose infusion
followed  by  at  least  3  months  of  multiple-dose  insulin  treatment  was  able  to  reduce  mortality  in
patients with type 1 or type 2 diabetes 105 106. The DIGAMI II study could not, however, confirm
these results 107. Furthermore, the Leuven Study showed that intensive insulin therapy lowered both
morbidity and mortality among critically ill patients with or without diabetes treated in a surgical
intensive care unit 108. Similar data are also available for patients treated in a medical intensive care
unit 109. But other data contradicts this 110.
These results started a debate as to whether the blood glucose control or the insulin itself had
improved these patients’ prognosis 111.  The  debate  is  certainly  relevant,  since  a  beneficial
vasodilatory effect of insulin on the vasculature has also been demonstrated 112. Importantly, recent
trials could show no decrease in short-term mortality of patients with AMI when glucose-insulin-
potassium infusions were given acutely 113 114.  More  trials  are  needed  to  obtain  answers  to  these
open questions.
2.3.2 Chronic hyperglycaemia
Long-term glucose control has for more than two decades been assessed with the HbA1c assay, a
method that has also become the gold standard for the determination of chronic hyperglycaemia 115.
The results of the DCCT and other similar trials have established a relationship between HbA1c and
the risk for diabetic complications in patients with type 1 diabetes 1 28 29 30 116.
HbA1c reflects average glycaemia over a period of a few months, explained by the fact that the
lifespan of an erythrocyte containing haemoglobin is approximately 120 days 117. However, no
accurate studies to actually test this hypothesis have existed until now 118. The ADA, the EASD, the
International Diabetes Federation (IDF), and the International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC) participated in the HbA1c–derived average glucose (ADAG), study
that explored the relationship between the daily average blood glucose measured by the CGMS and
the HbA1c, in order to be able to accurately standardize the HbA1c measurement
119.
In the current recommendations for the treatment of patients with diabetes, the target level of HbA1c
is set at less than 7% 70. Nevertheless, not even half the patients with diabetes have achieved or will
achieve this goal 120. Improvement of glucose control is a great challenge for any physician.
2.3.2.1 Inflammation
Chronic inflammation is suggested to explain at least in part the enhanced cardiovascular mortality
of patients with type 1 diabetes 121 122 123. It is therefore not surprising that inflammatory markers
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such  as  CRP  and  Il-6  are  elevated  both  in  patients  with  type  2  diabetes  and  with  cardiovascular
disease 124 125. Growing evidence also suggests that that inflammatory markers are increased in
patients with type 1 diabetes with and without microvascular disease 126 127.
In addition, soluble intercellular adhesion molecule 1 (ICAM-1) and soluble tumor necrosis factor 
(TNF- ) predict risk for cardiovascular disease in non-diabetic subjects 128 129 and are increased in
patients with type 1 and type 2 diabetes 130 131. Notably, a recent publication from the DCCT study
demonstrated that tight glycaemic control reduced the concentrations of ICAM-1 132.
2.3.2.2 Endothelial dysfunction
To what extent chronic hyperglycaemia affects endothelial function is not yet fully unraveled.
Endothelial function cannot be measured directly in humans, but some information may be obtained
indirectly by measuring endothelium-dependent and independent vasodilation, plasma levels of
endothelium-derived regulatory proteins, or possibly microalbuminuria 133. Measurement of arterial
stiffness has also been considered an applicable method to measure endothelial function indirectly
134. The number of methods available to measure endothelial function, however, make the
interpretation and the comparison of results rather difficult and hazardous.
Patients with diabetic complications such as nephropathy, retinopathy, and atherosclerosis are
known to have disturbed endothelial function 135 136. Altered endothelial function is also suggested
to be related to increased mortality in patients with type 2 diabetes 137.  Furthermore,  Elliot  et  al.
demonstrated that endothelial dysfunction is present in patients with type 1 diabetes and
microalbuminuria 138. In contrast, it is not entirely clear whether patients with uncomplicated type 1
diabetes already show endothelial dysfunction. This may in part be due to the fact that autonomic
dysfunction modulates results 139 140 141.  Consequently,  the  blood  vessels  of  patients  with  type  1
diabetes may actually dilate, not constrict, and thus cause increased microvascular blood flow in
response to chronic hyperglycaemia 142.
All in all, the exact pathogenic mechanisms for these findings remain unresolved, but
hyperglycaemia may be a plausible trigger of endothelial dysfunction, as well as of chronic
inflammation and oxidative stress and may thus serve as the mediator of the endothelial damage.
2.3.2.3 Oxidative stress
Another potential mechanism by which chronic hyperglycaemia could cause diabetic complications
is through overproduction of superoxide and oxidative stress. Oxidative stress was linked to
diabetes as early as in 1979 143. What has, however, been discussed is whether oxidative stress
precedes the appearance of complications or whether it merely reflects the presence of
complications 144. A few studies have shown that in children and adolescents with type 1 diabetes,
increased oxidative reactions are already present 145 146, although conflicting data are also available
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147. At least, superoxide production is suggested to decrease in response to improved glycaemic
control in adult patients with type 1 diabetes 148.
Four major molecular mechanisms have been implicated in glucose-mediated vascular damage. All
seem to reflect hyperglycaemia-induced overproduction of superoxide by the mitochondrial
electron-transport chain. Excess superoxide partially inhibits the glycolytic enzyme GADPH, and
thereby diverts upstream metabolites (glucose, fructose-6-phosphate, glyceraldehyde-3-phosphate)
from glycolysis to the following pathways: the polyol pathway, the hexosamine pathway, the






























iii) Protein kinase C pathway
Figure 1. Four major pathways of hyperglycaemic damage mediated by oxidative stress. Adapted
by permission from Macmillan Publishers Ltd: Nature. Brownlee M et al. 2001;414(6865):813-820,
copyright 2001. www.nature.com.
In the polyol pathway, the enzyme aldose reductase is the key player. This enzyme normally
catalyses the NADPH-dependent reduction of toxic agents in the cell, but when the intracellular
glucose concentration is elevated, aldose reductase instead turns glucose into fructose. This next
reduces the NADPH available for glutathione reductase, and since NADPH is required to regenerate
reduced glutathione, reduced NADPH may lead to increased intracellular oxidative stress 150 151.
The hexosamine pathway is also activated by a high intracellular glucose concentration. The
fructose 6-phosphate is diverted from the glycolysis and then converted into glucosamine 6-
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phosphate by the enzyme GFAT (glutamine:fructose-6-phosphate amidotransferase) and finally to
UDP N-acetyl glucosamine. These biochemical changes are thought to disturb, among others, the
function of cardiomyocytes in the heart 152.
In the protein kinase C pathway intracellular hyperglycaemia raises the amount of diacylglycerol
(DAG),  and  DAG then  activates  PKC.  PKC exerts  a  variety  of  effects  on  gene  expression.  It  for
example reduces the production of endothelial nitric oxide (NO) and raises the production of ET-1.
It may also lead to increased capillary occlusion, angiogenesis, or inflammation 153 154 155.
Experimental animal models show that inhibition of PKC-  prevents alterations in the diabetic eye
and kidney 156. However, in vivo studies blocking this pathway with PKC-  inhibitors
(ruboxistaurin) have been unsuccessful in preventing the progression of diabetic retinopathy 157.
The nonenzymatic protein glycation pathway leads to the activation of advanced glycation end-
products (AGEs) through oxidative reactions, and these AGEs cause irreversible chemical changes
in proteins 158. The AGEs may harm the cell in three ways. Firstly, they modify proteins involved in
gene transcription 159. Secondly, they can diffuse out of the cell and modify the extracellular matrix,
thus causing cellular dysfunction 160. Thirdly, the AGEs may alter proteins circulating in the blood,
for example albumin 161. Importantly, Hammes et al. have shown that by inhibiting AGEs in
experimental animals, it is possible to prevent structural changes in diabetic retinopathy 162.
Inhibition of oxidative stress generated by the mitochondria abolishes all four pathways; the
overproduction of superoxide by the mitochondrial electron-transport chain may be the common
activator of the cascades, eventually leading to vascular complications 13 (Figure 1).
2.3.3 Glucose variability
Patients with diabetes show substantial fluctuations in their blood glucose profile throughout the
day. In spite of this, very few in vivo studies have investigated the role of glucose variability as a
risk factor for diabetic complications. There are, however, in vitro studies suggesting that glucose
variability activates cellular changes through the pathways shown in Figure 2 163 164. Furthermore,
the clinical difficulties in controlling the HbA1c raise an important question: Whether it would it be
better to target glucose variability rather than HbA1c in order to prevent complications.
An Australian study found a correlation between glucose variability and short-term mortality in
critically ill non-diabetic patients 9. These results are consistent with the fact that postprandial
hyperglycaemia is a risk factor for cardiovascular disease in type 2 diabetes 7 165.
In  contrast,  Kilpatrick  et  al.  showed  very  recently  in  patients  with  type  1  diabetes  that  glucose
variability influences neither the risk for microvascular nor for macrovascular complications 10 11.
However, daily glucose fluctuations are associated with an activation of oxidative stress in patients
with type 2 but not with type 1 diabetes 166 167. In a recent study by Ceriello et al. oscillating glucose
clearly altered endothelial function and oxidative stress both in patients with type 2 diabetes and in
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non-diabetic control subjects 168.  No  study  has  yet  shown,  in  patients  with  type  1  diabetes,  a
correlation between glucose variability and long-term or short-term complications.
2.4 Intermediate markers of macrovascular disease
Early detection of diabetic complications is essential in order to start protective treatment as early as
possible. A number of intermediate or surrogate markers for vascular complications may therefore
be useful for detection in patients with diabetes who show no clinical signs of complications.
Arterial stiffness, hypertension, and a prolonged QT time served as intermediate markers to
measure vascular complications in the present studies.
2.4.1 Arterial stiffness
2.4.1.1 Definition
The term arterial stiffness indicates that the capability of the arteries to expand and contract during
the cardiac cycle is reduced.
2.4.1.2 Molecular mechanisms
Two extracellular proteins, collagen and elastin, are the main determinants of the physical
properties of the arteries 169. A balance between these two proteins is regulated by specific enzymes:
metalloproteases. Hypertension leads to increased collagen production and eventually to stiffer
arteries 170.  Elastin,  on  the  other  hand,  provides  the  arteries  with  some of  their  elastic  properties.
Metalloproteases destroy elastin molecules and thereby increase arterial stiffness 171. AGEs have
also been shown to contribute to arterial stiffening by their formation of irreversible compounds
through non-enzymatic reactions between the proteins, collagen and elastin, and glucose 172.
2.4.1.3 Inflammation
A link between stiff arteries and chronic inflammation was recently shown through associations
between arterial stiffness and CRP, TNF- , and Il-6 concentrations in non-diabetic individuals 173
174 175. Stiffness of the large arteries was also associated with CRP in healthy individuals 176 177.
These results are in line with the fact that both CRP, TNF- , and Il-6, as well as arterial stiffness,
are risk factors for diabetic macrovascular disease 85 86.
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2.4.1.4 Endothelial dysfunction
Arterial stiffness is closely linked to endothelial function and smooth muscle tone in the arteries 178.
The endothelium consists of a single cell layer that separates the blood from the other tissue of the
arteries 179, and is an important endocrine organ with autocrine, paracrine, and endocrine functions.
The functional role of the endothelial  cells  differs according to the location of the arteries.  In the
large arteries, the endothelium is important for inflammatory processes and lipid metabolism.
In the resistance arteries, the endothelium regulates blood flow and blood pressure. This regulation
is partially mediated by endothelium-derived vasoactive substances, including prostacyclins,
vascular endothelial growth factors, interleukins, nitric oxide (NO), endothelin, ACE, and the von
Willebrand factor.
In the capillary bed, the endothelial cells transport nutrients and hormones such as glucose, fat, and
insulin 180.
Endothelial dysfunction is characterized by the loss of endothelium-dependent vasodilatation, partly
through decreased NO production, and results in increased arterial stiffness 181.  This is considered
to represent an early phase in the pathogenesis of cardiovascular disease 182. Pulse wave analysis
can measure endothelial function indirectly 183.
2.4.1.5 Oxidative stress
Studies that investigate markers of oxidative stress and arterial stiffness are few, although it is well
known that oxidative stress is a key event in the pathogenesis of diabetic complications 13. Kampus
et al. demonstrated associations between arterial stiffness and oxidized low-density lipoprotein
(OxLDL), a marker of oxidative stress, in non-diabetic subjects 184. Matsuo et al. reported that both
arterial stiffness (pulse wave velocity), and oxidative stress (malondialdehyde LDL), were
significantly decreased after four weeks of treatment with statins in non-diabetic patients with
hypercholesterolemia 185. Further studies are needed to clarify whether and how oxidative stress
may be linked to arterial stiffness in patients with type 1 diabetes.
2.4.1.6 Arterial stiffness measured by applanation tonometry
Arterial stiffness can be measured by several methods: ultrasonography, magnetic resonance
imaging, calculation of the ambulatory arterial stiffness index, and pulse contour analysis.
Applanation tonometry is a widely used non-invasive method. Pulse wave analysis (PWA) is used
to estimate systemic arterial stiffness by analyzing peripheral arterial pressure waveforms.
Applanation  tonometry  can  also  be  used  to  measure  pulse  wave  velocity  (PWV)  that  reflects  the
elasticity of both large (aortic) and intermediate (brachial) sized arteries.
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Arterial stiffness is measured by PWA; it is associated with coronary artery disease 186 and is a risk
factor for cardiovascular disease in patients with established coronary artery disease 187. It is also a
predictor of cardiovascular disease in patients with end-stage renal disease 188 and is consequently a
useful surrogate marker for macrovascular disease.
PWV is an independent predictor of cardiovascular disease both in patients with hypertension and
in ones with end-stage renal disease 189 190. It is, moreover, an independent predictor of mortality in
patients with diabetes as well as in the elderly and even in the general population 191 192 193, and can
therefore serve as an intermediate marker for macrovascular disease.
2.4.1.7 Risk factors for arterial stiffening
The most powerful risk factor for increased arterial stiffness is age 194. Another important
independent risk factor as shown in a number of studies is hypertension 195 196. Of note, increased
stiffness of the aorta is a risk factor for progression from normal blood pressure to hypertension in
the general population 197, in which hypercholesterolemia, as well, correlates with increased arterial
stiffness 198. Data also show that patients with type 1 diabetes have stiffer arteries than do non-
diabetic subjects 199 200 201 202 203. Regular physical activity protects from arterial stiffening in non-
diabetic subjects according to Tanaka et al 204. Acute stiffening of the arteries during smoking
occurs both in smokers and in non-smokers 205 206. Not only active but also passive smoking leads
to increased arterial stiffness over time 207 208. Moreover, the metabolic syndrome 209 (characterized
by a clustering of independent cardiovascular risk factors such as central obesity, hypertension,
impaired glucose regulation and dyslipidaemia) correlate with arterial stiffening in the general
population 210.
2.4.1.8 Treatments affecting arterial stiffness
A wide range of pharmacological and non-pharmacological agents have been used to reduce arterial
stiffness 211. Pharmacological treatment include antihypertensive drugs, hypolipidemic agents, and
antidiabetic agents 212. The Conduit Artery Function Evaluation (CAFE) study showed an important
difference in augmenatation index (Aix) and central blood pressure in hypertensive diabetic and
non-diabetic patients treated with -blockers compared with those taking calcium antagonists 213. -
blockers did not reduce AIx and central BP, but calcium antagonists did. Speculatively this was due
to the inability of -blockers to reduce the magnitude of the reflection wave 214. This finding is in
line with those from the Losartan Intervention For Endpoint Reduction (LIFE) study demonstrating
that ACE inhibitors are more effective than -blockers in reducing left ventricular hypertrophy and
its consequences 215. In addition, preliminary data show beneficial effects of the so-called AGE-
breakers on arterial stiffness, a finding that may be of importance especially for patients with
diabetes 216.
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Non-pharmacological treatments include exercise, weight loss, a low-salt diet, moderate alcohol
consumption,  and  hormone  replacement  therapy,  as  well  as  alternative  treatment  options  such  as
garlic powder, dark chocolate, and fish oil 217.
2.4.2 Hypertension
Both epidemiological studies and clinical trials have shown that hypertension is an independent risk
factor for micro- and macrovascular disease in diabetes. In the general population, a higher risk for
cardiovascular disease begins already at blood pressure values as low as >115/75 mmHg 218. The
Hypertension Optimal Treatment (HOT) trial showed that patients with diabetes should maintain a
diastolic blood pressure below 80 mmHg 219. The current guidelines set their target at <130/80
mmHg 220. Multiple studies have shown in patients with diabetes, that antihypertensive agents
protect from microvascular and macrovascular disease 221. However, the consensus stands that ACE
inhibitors (or ARBs) are the drugs of choice in the management of blood pressure in diabetes with
or without diabetic nephropathy 222.
2.4.2.1 Pulse pressure
Pulse pressure (PP) is defined as the difference between the systolic (SBP) and the diastolic (DBP)
blood pressure, and starts to increase after the age of 55 to 60 years due to a stiffening of the arteries
as part of normal ageing 223. It is a predictor of cardiovascular disease in the general population 224,
and in elderly people it has even stronger predictive value than systolic or diastolic pressure alone
225. The PP has been shown to be associated with the inflammatory markers Il-6 and CRP in healthy
men 226 227. Interestingly, patients with type 1 diabetes show an accelerated ageing of the arteries, a
phenomenon that in part may explain their enhanced risk for cardiovascular disease 228. In the
Finnish Diabetic Nephropathy (FinnDiane) Study, the finding was evident both in females and
males. In fact, the PP already started to increase 15 to 20 years earlier in patients with type 1
diabetes than in non-diabetic controls.
2.4.3 Prolonged QT interval
QT time on the electrocardiogram (ECG) reflects the total duration of ventricular myocardial
depolarisation and repolarisation. The heart-rate corrected QT time (QTc) is shown to predict
cardiovascular mortality in healthy subjects as well as in patients with types 1 and 2 diabetes 12 229.
Hence, in these patients, the QTc interval can be serve as an intermediate non-invasive marker of
cardiovascular risk.
A few risk factors for QTc prolongation have been identified in the general population, including
high blood pressure, female sex, genetic susceptibility, and ischaemic heart disease 230 231 232. In the
EURODIAB prospective complications study, female sex, HbA1c, and systolic blood pressure were
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confirmed  as  risk  factors  for  a  prolonged  QTc  in  patients  with  type  1  diabetes.  Clearly,  physical
activity  and  a  lower  BMI  play  a  protective  role 233. QTc time is also associated with diabetic
nephropathy and autonomic neuropathy in patients with type 1 diabetes 232.
2.4.3.1 Short-term hyperglycaemia and QT time
Hypoglycaemia is associated with a prolonged  QTc interval 234. It is possible that risk of sudden
death, the so-called ”dead in bed” syndrome 235 seen in patients with type 1 diabetes is due to their
prolonged QTc time. Marfella et al. in turn reported that acute hyperglycaemia prolongs QT time
also in non-diabetic subjects, with similar results in rats 236 237. Di Filippo et al. reported that
reversal of QT-interval prolongation during acute hyperglycaemia caused by either a specific
antioxidant or a endothelin-1 receptor antagonist occurred in rats, suggesting that oxidative stress
and endothelial dysfunction are key events in the process 238 239. Hence, a link between acute
hyperglycaemia and the QTc interval may be oxidative stress, which in turn activates a sympathetic
response. Whether chronic hyperglycaemia acts in the same way is still unclear.
2.5 Pre-eclampsia
Pre-eclampsia, a serious disorder that complicates 3 to 5% of all pregnancies 240 241, is characterized
by hypertension, proteinuria, and endothelial dysfunction appearing during the second half of
pregnancy 242. The incidence of pre-eclampsia in patients with type 1 diabetes is higher than in
pregnant nondiabetic women, generally exceeding 10% 243. Pregnancy-induced hypertension (PIH)
is also twice as common in patients with type 1 diabetes as in non-diabetic individuals 15.
The pathogenesis of pre-eclampsia is not fully understood, but according to one hypothesis,
insufficient invasion of the placental cytotrophoblasts into the uterine spiral arteries causes placental
ischaemia, which in turn causes a release of yet-unknown vasoactive factors. These substances
damage the maternal endothelium and cause widespread impairment of endothelial function 244.
In patients with type 1 diabetes, the most important risk factors for pre-eclampsia are prepregnancy
microalbuminuria, or proteinuria 245 246 247. Other predictive factors are retinopathy, poor glycaemic
control, nulliparity, and long duration of diabetes 248. Although the clinical manifestations of pre-
eclampsia  disappear  after  delivery,  endothelial  dysfunction  seems  to  persist  even  years  after  pre-
eclamptic pregnancy 249.
Importantly, a history of pre-eclampsia elevates the risk for cardiovascular morbidity and mortality
in the general population, but only a few studies have focused on the effects of pre-eclampsia on the
microvascular complications in type 1 diabetes 250 251 252 253. Pregnancy itself does not seem to be a
major cause of diabetic microvascular complications 254. Lovestam-Adrian et al. showed that pre-
26
eclampsia on the other hand aggravates diabetic retinopathy, but patients in that study were
followed for only 6 months after delivery 255. A small retrospective study showed that proteinuria
but not preeclampsia is a risk factor for nephropathy in women with type 1 diabetes 256. Whether
pre-eclampsia leads to diabetic nephropathy is thus still unclear.
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3 Aims of the study
The aims of the present studies were to learn:
I.  Whether acute hyperglycaemia influences arterial stiffness in patients with type 1 diabetes.
II. Whether daily blood glucose fluctuations influence central and peripheral blood pressure as well
as arterial stiffness.
III. Whether acute hyperglycaemia disturbs myocardial repolarization in patients with type 1
diabetes.
IV. Whether inflammatory markers respond to acute hyperglycaemia.
V. Whether pre-eclampsia and pregnancy-induced hypertension predict diabetic nephropathy in
























Figure 2. Glycaemia, intermediate markers, and diabetic complications. Roman numerals refer to
the five (V) studies.
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4 Subjects and study design
4.1 Ethical aspects
All  studies  were  approved  by  the  Ethics  Committee  of  the  Hospital  District  of  Helsinki  and
Uusimaa. All subjects gave their written informed consent prior to participation.
4.2 Young patients with type 1 diabetes (I-IV)
The clinical characteristics of all patients are shown in Table 1. Twenty-two male patients with type
1 diabetes were recruited from the FinnDiane study. All these patients participated in Studies I to V.
The FinnDiane is a nationwide multicenter study exploring clinical, environmental and genetic risk
factors for type 1 diabetes and its complications. All subjects were between 18 and 40 years of age.
Exclusion criteria were smoking, hypertension, arrhythmias, diabetic complications, any medical
treatment (except insulin), and acute infections. Incipient or overt diabetic nephropathy was ruled
out by review of all available urine collections for AER prior to the study visit. Only patients who
fulfilled the criteria of a normal AER (<20 g/min or <30 mg/24h) in two of three overnight or 24 h
urine collections were selected. Absence of diabetic retinopathy was verified from their medical
files.  ECG  was  recorded  from  all  study  subjects,  and  all  recordings  were  normal.  The  patients
attended a thorough clinical investigation including blood samples. Their blood glucose
concentration was monitored for 72 h, after which they underwent at 2 h hyperglycaemic clamp.
4.3 Healthy Volunteers (I-IV)
Table 1 shows the clinical characteristics of the healthy volunteers. Thirteen healthy males served
as control group. They were age-matched non-smoking medical students. After a clinical
investigation similar to the one performed on patients with type 1 diabetes, a 2 h hyperglycaemic
clamp was performed. Normal ECGs were recorded for all the healthy volunteers.
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Table 1. Descriptive characteristics of patients and healthy volunteers (Studies I-IV).
Patients with type 1 diabetes Healthy volunteers
Age (years) 25.9 ± 5.6 25.4 ± 1.4
Height (cm) 179 ± 6 181 ± 5
BMI (kg/m2) 23.5 ± 3.4 24.0 ± 1.7
HbA1c (%) 7.4 ± 0.9a 5.2 ± 0.3
SBP (mmHg) 123 (116-139) 126 (117-136)
DBP (mmHg) 73 (67-78) 72 (67-78)
Serum cholesterol (mmol/l) 4.3 ± 1.0 4.3 ± 0.7
Serum LDL-cholesterol (mmol/l) 2.2 ± 1.0 2.2 ± 0.7
Serum HDL-cholesterol (mmol/l) 1.7 ± 0.4 1.7 ± 0.4
Serum triglycerides (mmol/l) 0.7 (0.6-1.2) 0.6 (0.5-1.0)
Serum creatinine (µmol/l) 72.6 ± 12.9 b 83 ± 12.0
Albumin excretion rate (mg/24h) 2.0 (0.0-13.2) 0.0 (0.0-4.0)
Duration of diabetes (years) 9.5 ± 4.4 -
Data are presented as mean ± SD or median with interquartile range. a P<0.001, and b P<0.01 for change in parameters. BMI = body
mass index, DBP = diastolic blood pressure, SBP = systolic blood pressure.
4.4 Women with type 1 diabetes followed during their pregnancy (V)
The  clinical  characteristics  of  the  patients  during  pregnancy  and  at  follow-up  time  are  shown  in
Table 2. The patients (n=429) included at baseline were women with type 1 diabetes who were
followed throughout their pregnancy and delivery at the Department of Obstetrics and
Gynaecology, Helsinki University Central Hospital during the period 1988 to 1996. In the greater
Helsinki area with its population of 1.5 million inhabitants, this is the only center responsible for
the obstetric care of women with type 1 diabetes. Out of the 429 baseline patients, 366 had one, 46
had two, and 17 had more than two childbirths (total number of deliveries 590). Some patients
could not be tracked; seven had died before the present study, but follow-up data could be retrieved
for all seven. The number of patients invited to the follow-up was 396, of whom 196 accepted the
invitation.
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Age (years) 31.1 ±5.2 28.3 ±4.0a 28.6 ±5.2b
BMI (kg/m2) 22.5 ±2.8 22.9 ±2.1 23.8 ±3.2b
Gestational age at delivery (weeks) 37.5 ±1.4 36.3 ±1.7a 37.1 ±1.6
Birth weight Z-score (Sd) 1.2 ±1.9 1.3 ±1.9 1.7 ±1.6
Birth weight (g) 3725 ±811 3433 ±852 3811 ±621
HbA1c prepregnancy (%) 7.5 ±1.1 7.7 ±0.9 7.3 ±0.7
HbA1c I trimester (%) 7.5 ±1.3 8.1 ±1.2 7.0 ±1.6
HbA1c II trimester (%) 7.0 ±1.1 7.3 ±0.9 7.1 ±1.3
HbA1c III trimester (%) 7.2 ±1.2 7.5 ±1.2 7.4 ±1.4
Nulliparity (%) 55.2 81.4b 75.0
Follow-up
Age (years) 41.7 ±6.6 37.9 ±5.9 b 39.5 ±5.6
BMI (kg/m2) 24.9 ±4.3 24.6 ±3.3 25.8 ±4.2
Duration of diabetes (years) 24.1 ±8.6 26.8 ±7.5 24.4 ±9.6
SBP (mmHg) 128 ±15 133 ±14 131 ±16
DBP (mmHg) 76 ±10 80 ±8b 79 ±8
Serum Total cholesterol (mmol/l) 4.7 ±0.8 4.7 ±0.8 4.7 ±0.7
Serum HDL-cholesterol (mmo/l) 2.0 ±4.7 1.8 ±0.5b 1.9 ±0.4
Serum LDL-cholesterol (mmol/l) 2.4 ±0.6 2.5 ±0.8 2.4 ±0.6
Serum Triglycerides (mmol/l) 0.7 [0.3-1.6] 0.9 [0.4-3.1] b 0.9 [0.3-2.1] b
HbA1c (%) 8.6 ±1.5 8.8 ±1,3 8.7 ±1.6
Serum Creatinine (µmol/l) 74.7 ± 16.0 93.3 ± 55.5b 74.5 ± 12.0
AER (mg/24 h) 16.8 [0.1-116] 43.6 [2-293] 9.9 [4.4-18.0]
Smokers (%) 21.7 15.4 32.3
Antihypertensive treatment (%) 9.8 50.0a 41.9a
Diabetic nephropathy (%)c 8.9 41.9a 10.3
Coronary heart disease (%) 2.2 12.2b d 3.2
Myocardial infarction (%) 0 7.3b d 3.2
Data are means ± SD or median with interquartile range. aP<0.001 and bP<0.05 vs Normotensive pregnancy. Patients with
prepregnancy hypertension were excluded from the analysis (N=23). cWhite F excluded, dFisher’s exact test used. SBP = systolic





Type 1 diabetes was defined as a diagnosis of type 1 diabetes with age at onset less than 40 years,
and insulin therapy initiated within one year (I-IV). In Study V, type 1 diabetes was defined in the
same manner despite the fact that age at onset was less than 35.
5.1.2 Hypertension
Essential hypertension was defined as a systolic blood pressure 140 mmHg or diastolic blood
pressure 90 mmHg or the use of antihypertensive medication in the patients with type 1 diabetes
and control subjects (I-V).
5.1.3 Pre-eclampsia and pregnancy-induced hypertension (V)
Pre-eclampsia was defined as elevated blood pressure as described above accompanied by
proteinuria after 20 weeks of pregnancy. Pregnancy-induced hypertension was defined as elevated
blood pressure in the absence of proteinuria257 258.  Patients  with  hypertension  before  20  weeks  of
pregnancy were excluded from all analyses, and patients with proteinuria during the first half of
pregnancy (White´s class F) were excluded from the analyses involving nephropathy.
5.2 Pulse wave analysis and velocity (I, II, IV)
5.2.1 Pulse wave analysis
As the left ventricle of the heart contracts, it creates a forward pressure wave that travels to the
periphery throughout the arterial tree. As the pressure wave reaches the branching points of the
arteries, high-resistance arterioles and regions of increased arterial stiffness, it reflects backwards,
towards the heart 259. The reflected wave results in an arterial waveform that varies throughout the
arterial tree and can be measured as the pulse wave analysis. The reflected wave arrives back to the
aorta in elastic arteries during diastole, augmenting diastolic pressure and improving coronary
perfusion. As arterial stiffness increases, the reflected wave returns to the heart at an earlier phase of
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the cardiac cycle, augmenting, instead of the diastolic pressure, the systolic pressure, and causing a
reduction in coronary perfusion and an increase in cardiac oxygen consumption. This may, over
time, result in left ventricle hypertrophy and manifest heart disease.
Pulse wave analysis (PWA) was recorded by an applanation tonometer (SphygmoCor, Atcor
Medical, Sydney, Australia). This method estimates arterial stiffness by analyzing peripheral
arterial pressure waveforms with a high-fidelity micromanometer (SPC-301; Millar Instruments,
Houston, TX, USA) 260. The pressure waveforms were recorded from the radial artery of the right
arm with  the  wrist  slightly  extended  and  supported  on  a  pillow.  The  data  were  collected  directly
into a desktop computer and processed with the SphygmoCor software using a validated
generalized transfer function was based on a comparison with intra-arterial pressures in patients
having surgery. This function was then applied to generate the corresponding central aortic
waveform 261 262. The augmentation can be calculated as the difference between the second (caused
by wave reflection) and the first systolic peak (caused by ventricular ejection) (Figure 3). The
average of three consecutive readings, each consisting of at least 20 sequentially recorded
waveforms, served for the analyses. The augmentation index (AIx), a generally used variable to
estimate arterial stiffness, was then calculated by the software as the quota of the augmentation and
the central pulse pressure. Reproducibility of this method is in accordance with that reported by
other investigators 263 266. When the heart rate is high, the pulse wave reflection returns to the aorta
at an earlier phase of the cardiac cycle. Thus, heart rate and AIx are in an inverse association, and
AIx must be adjusted for heart rate to avoid inaccurate results 264 265. All measurements were
subjected to internal quality control by the software.
2. systolic peak




Figure 3. Pulse wave of aorta measured by applanation tonometer. DBP = diastolic blood pressure.
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5.2.2 Pulse wave velocity
Pulse wave velocity (PWV) is the speed at which the forward pressure wave is transmitted from the
aorta through the vascular tree. In order to measure arterial stiffness in large (aortic) and
intermediate (brachial) -sized arteries, the carotid-femoral (aortic) and carotid-radial (brachial)
pulse wave velocity pressure waveforms are recorded sequentially at both the carotid, femoral, and
radial arteries. This is performed with the SphygmoCor device by sequentially recording ECG-
gated carotid and femoral artery waveforms with a high-fidelity micromanometer for 30 seconds.
The difference between carotid-to-femoral and carotid-to-radial path length was estimated from the
distance from the sternal notch to the femoral and carotid palpable pulse. Assessment of pulse wave
analysis and pulse wave velocity represent a relatively simple technique that has been widely
applied and found to be robust and reproducible. The software calculated the pulse wave velocity as
previously described 266.
5.3 Blood pressure (I-V)
Aortic (central) blood pressure was also determined by applanation tonometry  (I, II, IV). Brachial
blood pressure was measured in duplicate from the left arm by a validated oscillometric
sphygmomanometer (Omron Corp, Bannockburn, IL, USA) (I-V). The mean of the recordings were
calculated and used for the analyses.
5.4 72 h continuous glucose monitoring (II)
A continuous glucose monitoring system (CGMS) was used to study the 72 h interstitial fluid
glucose profile. The CGMS system (Medtronic MiniMed, Sylmar, CA, USA) is accepted for use as
a Holter-type monitor and has been validated and accepted by the U.S. Food and Drug
Administration 267 268 269.  The  patients  were  told  to modify their usual daily behaviour as little as
possible during the test.  The system was well  tolerated by all  patients.  The CGMS is a minimally
invasive glucose sensing system that is inserted into the abdominal subcutaneous fat to record
interstitial fluid glucose concentrations between 2.2 and 22.0 mmol/l. The glucose monitor recorded
interstitial fluid glucose concentrations in each patient every fifth minute for 72 h and needed
calibration by four blood glucose values daily obtained by finger sticks. After 3 days, the data were
downloaded via the Com-Station by the MiniMed Solutions Software version 2.0b (Medtronic
MiniMed), and the 24 h glucose profile obtained for each of the 3 days was analyzed.  As an index
of hyperglycaemic episodes, the area under the curve for values exceeding 10 mmol/l (AUC+10)
was calculated from each 24 h glucose profile falling within the range (2.2-22.0 mmol/l). The area
under the curve below 5 mmol/l (AUC-5) was used for low glucose excursions, meaning
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hypoglycaemia (Figure 4) 270. Moreover, the glucose curves were manually inspected to verify that
the sensors had functioned as intended. The mean amplitude of glycaemic excursions (MAGE) was
calculated to describe glucose fluctuations during the day 271. MAGE detects major swings of
glycaemia but excludes minor ones. Calculation of MAGE was performed by measurement of the
arithmetic mean of the differences between consecutive peaks and nadirs. The analyses were
performed with in-house scripts in the Mathlab programming environment (MathWorks Inc, Natick,
MA, USA).
Figure 4. Schematic figure of hyperglycaemic episodes (AUC+10) and low glycaemic excursions
(AUC-5) by the continuous glucose monitoring system (CGMS).
5.5 2 h hyperglycaemic clamp (I-IV)
At the end of the 72 h glucose monitoring, the subjects visited the research centre. All subjects had
been instructed to fast overnight and, to refrain from smoking and from drinking alcoholic
beverages or coffee from the night before the study. They were instructed to take half of their long-
acting insulin dose (full dose in the case of glarginine insulin) in the morning. They rested for more
than 30 minutes prior to the clamp. Intravenous lines were inserted into a large antecubital vein of
the right arm for infusions and into a dorsal vein of the left arm for blood sampling.
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During the hyperglycaemic glucose clamp, blood glucose concentrations were acutely raised with a
bolus injection of 0.25 g/kg glucose (50% solution) followed by a variable 20% glucose infusion to
achieve steady-state plasma glucose levels of about 15 mmol/l for 120 minutes. Blood samples were
drawn every 10 minutes from retrograde cannulas (arterialized venous blood) to measure and adjust
the blood glucose levels (Beckman Instruments Inc, Fullerton, CA, USA).
The healthy volunteers were examined in the same manner except that prior to the glucose bolus
they received a 25 g bolus followed by a 0.5 g/min infusion of a somatostatin analogue
(Sandostatin , Novartis, Finland) to inhibit their endogenous insulin production. Somatostatin was
infused throughout the clamp through a third cannula inserted in the left arm (antecubital vein).
Measurements of blood pressure, arterial stiffness, and ECG were made before (at normoglycaemia)
and at 0, 60, and 120 minutes of hyperglycaemia (Figure 5). Blood samples were drawn at baseline
and at the end of the 2 h clamp. Additionally, in the healthy volunteers, an additional measurement
was made after the somatostatin analogue infusion but before the glucose bolus. All measurements
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Figure 5. Schematic figure of the 2 h hyperglycaemic clamp.
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5.6 Measurement of QT interval and dispersion (III)
The ECGs were recorded in the supine position from standard 12-lead bands at 50 mm/s, the
amplitude calibration being 10 mm/mV for all readings. Eight of the 12 leads were evaluated. In
each lead, three consecutive complexes were read. No recordings of extrasystoles or subsequent
beats were analyzed. The analysis was made according to the Minnesota code 272. All tracings were
analysed manually by the same physician (DG) twice in random order, and the physician was
blinded to all clinical data from individual patients. The QT interval length was measured from the
onset of the QRS complex to the end of the T wave. In the presence of U waves, the end of the QT
interval was set at the nadir of the curve between the T and the U wave. Maximal QT interval was
corrected for each heart rate by the Bazett formula (QTc Bazett = QT/RR
1/2) 273,  and in addition, the
formula suggested by Fridericia (QTc Fridericia = QT/RR
1/3) 274 and the Framingham formula derived
by linear regression (QTc Sagie = QT + 0.154(1-RR)
275.  The  QT  time  was  also  corrected  by  the
nomogram method (QTNc = QT + correcting number)
276.
QTc dispersion was calculated as an interlead variability of the QTc interval (QTc -dispersion =
QTc max - QTc min), reflecting the degree of inhomogeneity of myocardial repolarisation.
5.7 Biochemical analyses (I-V)
Haemoglobin, leukocyte count, HbA1c, lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol
and triglycerides), serum creatinine, potassium, sodium, calcium, and albumin were determined
from fasting blood samples. Haemoglobin, leukocyte count, potassium, sodium, calcium, and
albumin were measured by routine methods. HbA1c was analyzed by immunoturbidimetry (normal
range 4.0-6.0%). Serum lipids were measured by automated enzymatic methods with a Cobas Mira
analyzer (Hoffman-La Roche, Basel, Switzerland) and serum creatinine by routine enzymatic
methods. Serum insulin was measured by immunofluorometry. Urinary albumin excretion rate
(AER) was assessed from a 24 h urine collection by immunoturbidimetry.
Measurements of serum interleukin-6 (IL-6) and plasma tumor necrosis factor-  (TNF- ) were done
after storage at -20 ºC by immunochemoluminometry and serum-sensitive C-reactive protein (CRP)
by photometry all in duplicate. An acute phase inflammatory marker score was calculated as:  (C-
reactive protein+IL-6+TNF- )/3 277. Serum samples for determination of intracellular adhesion
molecule-1 (ICAM-1), vascular cellular adhesion molecule-1 (VCAM-1) and eSelectin were stored
at -20ºC until assayed. The concentrations were measured in duplicate with commercially available
immunosorbent  kits  (R&D Systems,  Minneapolis,  MN,  USA).  The  determination  of  endothelin-1
(ET-1)  was  also  done  in  duplicate  from  extracted  plasma  (stored  at  -20ºC)  (R&D  Systems).  The
samples for determination of serum superoxide dismutase (SOD) were stored at -80ºC according to
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manufacturer’s instructions, and measured with a commercially available kit (Cayman Chemical,
Michigan, MI, USA).
5.8 Assessments during pregnancy and at follow-up (V)
5.8.1 Blood pressure and kidney function during pregnancy
During pregnancy, blood pressure was measured at each visit in the sitting position after a 10-
minute rest. Measurements were made with a sphygmomanometer by midwives and nurses, and
blood pressure was considered elevated when the DBP was repeatedly 90 mmHg or if it increased
by a minimum of 15 mmHg during pregnancy. Urinary protein was measured by a dipstick method
at every visit. If the dipstick repeatedly showed ”+” or a ”++”, proteinuria was confirmed by a 24 h
urine collection. Proteinuria was defined as urinary protein excretion 300 mg/24h.
5.8.2 Glycaemic control during pregnancy
During pregnancy, HbA1c was measured monthly by HPLC (Diamat, Bio-Rad Laboratories,
Hercules,  CA,  USA).  The  normal  range  was  defined  as  HbA1c between 4.0 and 6.0%. The first
HbA1c assessment during pregnancy was carried out during the period between the 7
th and the 14th
week of gestation. The mid-pregnancy value was obtained between the 20th and the 25th week and
the third measurement approximately 2 weeks before delivery. The average HbA1c value of each
trimester was used in the analysis.
5.8.3 Medical history and kidney function at follow-up (FinnDiane visit)
Data on medication, cardiovascular status, and diabetic complications were recorded from a
standardized questionnaire completed by the patient´s attending physician and thus immediately
verified from the medical files. Coronary heart disease was defined as a positive history of
myocardial infarction, bypass operation, a diagnostic finding in angiography or positive exercise
test.
Classification of renal status was based on the AER in at least two of three urine-collections at
follow-up. Patients were defined as normoalbuminuric (n=135) if their AER was persistently <20
µg/min overnight or <30 mg/24h in the 24h urine collection. Microalbuminuria or incipient diabetic
nephropathy (n=24) was defined as an AER between 20 <200 µg/min or 30 <300 mg/24h,
whereas macroalbuminuria or established diabetic nephropathy (n=9) was defined as an AER 200
µg/min or 300 mg/24h. Patients on renal replacement therapy (dialysis or kidney transplantation)
were considered to have end-stage renal disease (ESRD) (n=2). Patients with either
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microalbuminuria, macroalbuminuria or clinical ESRD were pooled and considered in the analyses
to represent diabetic nephropathy.
5.9 Statistical methods
All analyses were performed with SPSS 13.0 (SPSS, Chicago, IL, USA). Power calculations were
performed to test the required size of the study population 278. Results are presented as mean ± SEM
or  ±  SD  for  normally  distributed  variables  and  as  median  (interquartile  range,  IQR)  for  non-
normally distributed variables. P-values <0.05 were considered statistically significant.
Differences between the groups for normally distributed variables were tested with ANOVA or
Student´s t-test and for non-normally distributed variables with appropriate tests. For categorical
variables the 2 test or Fisher´s exact test was used when appropriate (V). Simple linear regression
was used to examine univariate correlations (Pearson’s parametrical test, or Spearman’s non-
parametrical test). More complex correlations were analyzed by means of multivariate regression
analysis.
To detect differences in response to hyperglycaemia within and between the groups, a two-way
ANOVA for repeated measures was performed followed by a mixed effects model or Bonferroni’s
test adjusted for age (I,III). In Study IV, values at different time-points during the hyperglycaemic
clamp were compared with paired samples tests.
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6 Results
6.1 Clinical characteristics (I-IV)
The baseline clinical characteristics were shown in Table 1. As expected, patients with type 1
diabetes had higher HbA1c (7.4 ± 0.9% vs. 5.2 ± 0.3%, P<0.001) than did healthy volunteers. No
differences regarding age, BMI, lipid profile, blood pressure or AER were observable between
groups.
6.2 Haemodynamic variables in the study groups at baseline (I-IV)
The haemodynamic variables are depicted in Table 3. Patients with type 1 diabetes had stiffer
arteries at baseline (normoglycaemia) than did healthy volunteers after correcting for age (AIx; -5 ±
3% vs. -20 ± 5%, P<0.05) (I). Neither brachial, nor aortic PWV differed between groups at baseline.
A statistically significant difference appeared between patients with type 1 diabetes and healthy
volunteers regarding oxidative stress at baseline. No difference emerged in QTc (Table 3).
Table 3. Haemodynamic parameters in patients with type 1 diabetes and healthy volunteers at baseline.
Patients with type 1 diabetes (N = 22) Healthy volunteers (N = 13)
Brachial SBP (mmHg) 123 (116-139) 126 (117-136)
Brachial DBP (mmHg) 73 (67-78) 72 (67-78)
Brachial PWV (m/s) 7.1 ± 1.2 7.4 ± 1.7
AIx (%) -5 ± 3 a -20 ± 5
Aortic SBP (mmHg) 105 (99-114) 107 (98-117)
Aortic DBP (mmHg) 73 (67-80) 72 (68-78)
Aortic PWV (m/s) 6.5 (5.8-7.4) 6.5 (5.3-7.1)







Data are presented as mean ± SD or median with interquartile range. a P<0.05 for change in parameters. SBP = systolic blood
pressure, DBP = diastolic blood pressure, AIx = augmentation index, PWV = pulse wave velocity. Formulae for QTc Bazett were used.
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6.3 Acute hyperglycaemia and haemodynamic variables (I, III, IV)
Blood glucose concentrations during the clamp in patients with type 1 diabetes and non-diabetic
control subjects are shown in Table 4 and Figure 6. Serum insulin in patients with type 1 diabetes
increased from 0.3 to 0.6 mU/l during the clamp, while insulin secretion was blocked by the
somatostatin analogue in the healthy volunteers (3.3 to 7.2 mU/l).





0 min 60 min 120 min
T1D
Blood glucose (mmol/l) 6.7 (6.3-8.2) 17.3 (15.9-19.0)a 17.9 (17.1-20.1) a 17.9 (16.8-19.5)a
Brachial SBP (mmHg) 123 (116-139) 127 (121-136) 128 (118-136) 126 (121-138)
Brachial DBP (mmHg) 73 (67-78) 72 (66-80) 75 (69-79) 71 (68-80)
Brachial PP (mmHg) 53 ± 11 57 ± 13 a 55 ± 13 55 ± 9
Aortic SBP (mmHg) 105 (99-114) 110 (103-119) 107 (104-119) 107 (104-115) a
Aortic DBP (mmHg) 73 (67-80) 73 (68-83) 75 (69-79) 71 (68-84)
Aortic PP (mmHg) 31 (28-38) 35 (32-41) a 35 (30-41) a 38 (31-40) a
Healthy volunteers
Blood glucose (mmol/l) 5.1 (4.7-5.4) 16.6 (16.1-17.6)a 18.3 (17.6-19.3)a 16.6 (16.0-18.4)a
Brachial SBP (mmHg) 126 (117-136) 125 (118-134) 128 (117-134) 126 (119-131)
Brachial DBP (mmHg) 72 (67-78) 74 (67-81) 71 (62-78) 68 (63-71)
Brachial PP (mmHg) 56 ± 9.3 49 ±10.7 56 ± 7.3 57 ± 7.6
Aortic SBP (mmHg) 107 (98-117) 106 (103-119) 106 (98-118) 105 (100-111)
Aortic DBP (mmHg) 72 (68-78) 75 (68-82) 71 (63-80) 68 (64-73)
Aortic PP (mmHg) 34 (27-38) 34 (30-41) 36 (34-41) a 37 (34-43) a
Data are presented as mean ± SD or median with interquartile range. a P<0.05 for change in parameter 0, 60 or 120 min. of
hyperglycemia vs. normoglycemia. SBP = systolic blood pressure, DBP = diastolic blood pressure, PP = pulse pressure.
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Figure 6. Blood glucose concentration at different time-points in the two study groups. Duration of
hyperglycaemia: 0 to 120 min. T1D = Patients with type 1 diabetes, Controls = healthy volunteers.
Data are mean±SEM.
6.3.1 Arterial stiffness (I)
After 120 minutes of hyperglycaemia, AIx increased steeply from -5% (IQR, -20-2) at baseline to
8% (-1-13) (P<0.001, Figure 7A) in patients with type 1 diabetes. The same trend was observable in
healthy volunteers (-20% (-24-[-9]) vs. 6% (-6-11) , P<0.001, Figure 7A). Brachial PWV increased
during acute hyperglycaemia compared to normoglycaemia in the patients with type 1 diabetes (7.1
± 1.2 m/s vs. 8.0 ± 1.0 m/s, P<0.001), but not in the healthy volunteers (7.4 ± 1.7 m/s vs. 7,3 ± 1.4






Figure 7. AIx (A), Brachial PWV (B), and Aortic PWV (C) at different time-points in the two study
groups. Duration of hyperglycaemia: 0 to 120 min. T1D = Patients with type 1 diabetes, Controls =
healthy volunteers. Data are mean±SEM. * p<0.001 and † p<0.05 for change at 0, 60, and 120 min
of hyperglycaemia vs normoglycaemia.
6.3.2 Blood pressure (I)
Neither brachial systolic nor diastolic blood pressure changed during acute hyperglycaemia in either
group (Table 4). However, brachial pulse pressure increased in the patients with type 1 diabetes
during the clamp (53 ± 11 mmHg vs. 57 ± 9 mmHg, P<0.05), although it decreased in healthy
volunteers (56 ± 9 mmHg vs. 49 ± 8 mmHg, P<0.05). Notably, after 120 minutes of
hyperglycaemia, aortic PP increased from 31 (28-38) mmHg at baseline to 38 (31-40) mmHg
(P<0.05) in patients with type 1 diabetes and from 34 (27-38) mmHg to 37 (34-43) mmHg (P<0.05,
Figure 8) in healthy volunteers.
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Figure 8. Aortic pulse pressure at  different  time-points  in  the  two  study  groups.  Duration  of
hyperglycaemia: 0 to 120 min. T1D = Patients with type 1 diabetes, Controls = healthy volunteers.
Data are mean±SEM. † p<0.05 for change at 0, 60, and 120 min of hyperglycaemia vs
normoglycaemia.
6.3.3 QT time (III)
The QTc Bazett increased steeply both in patients with type 1 diabetes (390 ± 6 ms vs. 415 ± 5 ms,
P<0.05, Figure 9A) and healthy volunteers (378 ± 5 ms vs. 412 ± 8 ms, P<0.05, Figure 9A) when
the blood glucose was acutely elevated. The same trend was observed for QTc Fridericia and  QTc Sagie
(Table 5). An elevation in QT dispersion was evident at 60 min of hyperglycaemia in healthy
volunteers but not in patients with type 1 diabetes (Figure 9B). The PR interval did not change
during acute hyperglycaemia (Table 5). Serum calcium decreased from 2.27 ± 0.02 mmol/l at
baseline to 2.17 ± 0.02 mmol/l in patients with type 1 diabetes and from 2.27 ± 0.02 mmol/l to 2.13
± 0.02 mmol/l in non-diabetic subjects, at 120 min of hyperglycaemia (P<0.001). Furthermore,
serum potassium changed from 4.8 ± 0.1 mmol/l at baseline to 4.6 ± 0.1 mmol/l at 120 min of
hyperglycaemia (P<0.05) in patients with type 1 diabetes, but not in healthy volunteers (4.8 ± 0.1
mmol/l to 4.7 ± 0.1 mmol/l, NS).
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0 min 60 min 120 min
Serum sodium (mmol/l) 142 ± 0.6 136 ± 0.6 a
Serum potassium (mmol/l) 4.8 ± 0.1 4.6 ± 0.1c
Serum calcium (mmol/l) 2.27 ± 0.02 2.17 ± 0.02 a
QTc Fridericia (ms) 385 ± 10 406 ± 11 b 413 ± 11 b 396 ± 11
QTc Sagie (ms) 387 ± 7 407 ± 6 a 410 ± 6 a 403 ± 6 b
QTNc (ms) 391 ± 5 412 ± 5 b 410 ± 4 b 412 ± 4 b
Heart rate (beats/min) 62 ± 2 62 ± 2 60 ± 2 65 ± 3
PR time (ms) 158 ± 4 160 ± 4 159 ± 4 161 ± 4
Healthy volunteers
Serum sodium (mmol/l) 143 ± 0.5 139 ± 0.7 a
Serum potassium (mmol/l) 4.8 ± 0.1 4.7 ± 0.1
Serum calcium (mmol/l) 2.27 ± 0.02 2.13 ± 0.02 a
QTc Fridericia (ms) 401 ± 17 445 ± 12 a 441 ± 16 b 426 ±11 b
QTc Sagie (ms) 391 ± 9 426 ± 7 a 427 ± 11 a 420 ± 7 a
QTNc (ms) 382 ± 5 411 ± 5 b 416 ± 8 b 415 ± 6 a
Heart rate (beats/min) 58 ± 3 54 ± 2 56 ± 2 58 ± 2
PR time (ms) 164 ± 5 165 ± 5 168 ± 5 170 ± 4
Data are presented as mean ± SEM or median with interquartile range. a P<0.001, b P<0.01 and c P<0.05 for change in parameter 0,




Figure 9. The  QTc  interval  (A)  and  QTc  dispersion  (B) at different time-points in the two study
groups. Duration of hyperglycaemia: 0 to 120 min. T1D = Patients with type 1 diabetes, Controls =
healthy volunteers. Data are mean±SEM. † p<0.05 for change at 0, 60, and 120 min of
hyperglycaemia vs normoglycaemia. QTc calculated by Bazett’s formula.
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6.3.4 Inflammation (IV)
Il-6 increased during acute hyperglycaemia both in patients with type 1 diabetes (from 3.1 ± 1.1 to
4.3 ± 1.2 ng/l, P<0.01) and in healthy volunteers (from 2.3 ± 0.3 to 2.9 ± 0.4 ng/l, P<0.01) (Figure
10), but no change in CRP occurred in response to acute hyperglycaemia in either group. TNF-
increased in response to acute hyperglycaemia in patients with type 1 diabetes (3.4 ± 0.2 to 4.6 ±
0.8 ng/l, P<0.05) but not in healthy volunteers (3.9 ± 0.4 to 3.5 ± 0.4 ng/l, NS). The acute phase
inflammatory marker score was elevated during acute hyperglycaemia in patients with type 1






















Figure 10. Interleukin-6 (IL-6) during normoglycaemia and hyperglycaemia in both groups. Data
are mean ± SEM.  T1D = patients with type 1 diabetes, Controls = healthy volunteers.
6.3.5 Endothelial function (IV)
VCAM concentrations remained unchanged in response to acutely elevated glucose concentrations
both in patients with type 1 diabetes (498 ± 20 vs. 498 ± 21 ng/ml, NS) and in healthy volunteers
(535 ± 40 to 559 ± 39 ng/ml, P=NS). No change was observable in either ICAM or eSelectin in
either groups.
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6.3.6 Oxidative stress (IV)
Serum SOD levels were higher in patients with type 1 diabetes than in the non-diabetic control
subjects at baseline but showed no significant variation during the clamp (0.37 ± 0.03 vs. 0.39 ±
0.03 U/ml, NS) (Figure 11). However, in the healthy volunteers sSOD levels increased from a basal





















Figure 11. Superoxide dismutase (SOD) during normoglycaemia and hyperglycaemia in both
groups. Data are mean ± SEM. T1D = patients with type 1 diabetes, Controls = healthy volunteers.
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6.4 Glucose variability and vascular parameters (II)
6.4.1 Glucose variability and haemodynamic variables during normoglycaemia (II)
In the present study, we observed no correlation between MAGE (glucose variability) and any of
the measures of arterial stiffness (AIx, brachial or aortic PWV) in univariate regression analysis. A
univariate correlation was, however, apparent between HbA1c and AIx at baseline
(normoglycaemia).
Mean  daily  glucose  concentrations  and  aortic  PWV  correlated  positively  with  each  other  (Figure
12), but we found no univariate correlations between AUC+10 (postprandial hyperglycaemia) and
the haemodynamic variables. A negative correlation was, however, apparent between AUC-5 and
aortic PWV at baseline.
An independent association emerged between mean glucose concentrations and aortic PWV
(r=0.48, P<0.01) after adjustments for BMI, HbA1c, and duration of diabetes. This relationship was
independent of age, HR, SBP, HbA1c, and HDL-cholesterol but not of LDL-cholesterol. We further
observed independent relationships between AUC-5 and aortic PWV (r=-0.60, P<0.01) when
adjusted for BMI, HbA1c, and duration of diabetes in multivariate linear regression analysis.
Figure 12. Relationship between mean daily blood glucose concentration and aortic PWV (arterial
stiffness).
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6.4.2 Glucose variability and haemodynamic variables during acute hyperglycaemia (II)
The changes ( ) in haemodynamic variables measured between acute hyperglycaemia and baseline
values were calculated at both 0 and 120 minutes after the steady state level of hyperglycaemia was
reached (Table 6).
None of the measures of glucose control correlated with the change in arterial stiffness (AIx,
brachial and aortic PWV) during the clamp. A correlation between MAGE and both  aortic SBP
and  aortic DBP were observed at 0 minutes but not at 120 minutes.
The relationships between MAGE and  aortic SBP (r=0.62, P<0.05) and between MAGE and 
aortic DBP (r=0.52, P<0.01)  were  independent  of  BMI,  HbA1c, and duration of diabetes in
multivariate regression analysis. Independent relationships also appeared between MAGE and 
aortic SBP as well as between MAGE and  aortic DBP after adjustments for SBP, HbA1c, HDL-
cholesterol, and LDL-cholesterol.
No independent relationships appeared between HbA1c and changes in haemodynamic variables
during the clamp.
Table 6. Univariate correlation coefficients between a continuous glucose monitoring system and changes ( ) in central blood
pressure during acute hyperglycaemia. The changes ( ) in aortic BP between acute hyperglycaemia and baseline values were
calculated at both 0 and 120 minutes after the steady state level of hyperglycaemia was reached.
HbA1c MAGE Mean daily glucose
At 0 min of hyperglycaemia
 Aortic SBP 0.09 (0.01) 0.45 a (0.47 a) 0.19 (0.40)
 Aortic DBP -0.02 (-0.12) 0.43 a (0.57 a) 0.20 (0.58 a)
At 120 min of hyperglycaemia
 Aortic SBP 0.36 (0.37) 0.34 (0.21) 0.26 (0.15)
 Aortic DBP 0.21 (0.36) 0.16 (0.15) 0.21 (0.39)
a P<0.05. The values are univariate correlation coefficients. Correlation coefficients adjusted for HbA1c, brachial systolic blood
pressure, and HDL-cholesterol in the linear regression analysis in parenthesis. Changes ( ) in aortic BP between acute
hyperglycaemia and baseline values were calculated at both 0 and 120 minutes after the steady state level of hyperglycaemia was
reached. MAGE = mean amplitude of glycaemic excursions, SBP = systolic blood pressure, DBP = diastolic blood pressure.
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6.4.3 Glucose variability and biochemical analysis (II)
Positive univariate correlations appeared between HbA1c and MAGE, mean daily glucose
concentrations,  and  AUC+10 (Table  7).  In  addition,  mean daily  glucose  concentrations  correlated
positively with total cholesterol and LDL-cholesterol. AUC-5 correlated negatively with LDL-
cholesterol and positively with HDL-cholesterol.
The relationships between mean blood glucose and total cholesterol (r=0.42;P<0.05) as well as
LDL-cholesterol concentrations (r=0.42;P<0.05) were independent of BMI, HbA1c, or duration of
diabetes in multivariate regression analysis. The correlation between AUC-5 and LDL-cholesterol
(r=-0.47;P<0.05) was also independent.
Table 7. Univariate correlation coefficients between a continuous glucose monitoring system and biochemical analysis.
AUC+10 (>10mmol/l) AUC-5 (<5mmol/l) MAGE Mean daily glucose
HbA1c 0.64 a 0.02 0.48 b 0.52 a
Total cholesterol 0.21 -0.39 -0.10 0.43 b
LDL-cholesterol 0.19 -0.45 b -0.11 0.56 b
HDL-cholesterol -0.04 0.47 b 0.19 -0.10
Triglycerides 0.17 -0.31 -0.06 0.16
a P< 0.01 and b P< 0.05. AUC+10 = area under the curve for glucose values exceeding 10 mmol/l, AUC-5 =  area under the curve for
glucose values below 5 mmol/l, MAGE = mean amplitude of glycaemic excursion, LDL = low-density lipoprotein, HDL = high-density
lipoprotein, eGFR = estimated glomerular filtration rate.
6.5 Pre-eclampsia and diabetic nephropathy
6.5.1 Clinical characteristics of women with type 1 diabetes followed during pregnancy (V)
No clear differences appeared in baseline characteristics between patients participating in the
follow-up study and those not participating. Clinical characteristics are shown in Table 2. The
average follow-up time from the pregnancy to the follow-up visit was 10.6 ± 2.5 years. Patients
with pregnancy-induced hypertension had a higher BMI than patients with uncomplicated
pregnancies. Women with pre-eclampsia were younger and more often nulliparous than were
patients in the other groups.
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6.5.2 Pre-eclampsia and diabetic complications (V)
Women with pre-eclampsia were more likely to have diabetic nephropathy at follow-up than
women with an uncomplicated pregnancy (41.9% vs. 8.9%, P<0.001, Table 2). Women with a
history of pre-eclampsia had a higher frequency of coronary heart disease (12.2% vs. 2.2%,
P<0.05). The same trend was observed with the number of patients on antihypertensive treatment at
follow-up (50.0% vs. 9.8%, P<0.001).
Pre-eclampsia (p<0.001) and HbA1c (all three trimesters) (p<0.05) during pregnancy were
independently associated with diabetic nephropathy after adjustments for age, duration of diabetes,
smoking, BMI, and follow-up time (Table 8).
Table 8. Logistic regression analysis for diabetic nephropathy.
adjusted OR 95% CI P-value
PE a 7.7 1.6-36.1 0.01
HbA1c I trimester b 3.2 1.3-7.9 0.01
HbA1c II trimester b 4.0 1.7-9.8 0.002
HbA1c III trimester b 2.0 1.1-3.8 0.03
a Adjusted for BMI, follow-up time, smoking, duration of diabetes, age, and the average of the HbA1c measurements during all 3
trimesters.
b Adjusted for BMI, follow-up time, smoking, duration of diabetes, and age.
6.5.3 Pregnancy-induced hypertension and complications (V)
Patients with pregnancy-induced hypertension were more often on antihypertensive treatment
(41.9% vs. 9.8%, p<0.001, Table 2) than those with normal blood pressure during pregnancy. These
patient groups did not differ with regard to diabetic nephropathy at follow-up (10.3% vs. 8.9%, NS).
6.5.4 Pregnancy characteristics and outcome (V)
Higher HbA1c levels during pregnancy were associated with diabetic nephropathy (p<0.001). A
large difference between HbA1c during pregnancy and at follow-up predicted nephropathy at follow-
up, supporting the role of glucose exposure as a risk factor for diabetic nephropathy.
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7 Discussion and Conclusions
The novel findings of this thesis show that acute hyperglycaemia causes arterial stiffness both in
patients with uncomplicated type 1 diabetes and non-diabetic subjects. The hyperglycaemia-induced
inflammatory response may in part explain this finding. An acutely elevated blood glucose
concentration leads to impaired ventricular repolarisation associated with sudden death.
Furthermore, high mean daily blood glucose but not glucose variability per se is associated with
arterial stiffness. While glucose variability in turn correlates with the central blood pressure, these
results suggest that the glucose metabolism is closely linked to the haemodynamic changes in
young patients with type 1 diabetes. Finally, a history of a pre-eclamptic pregnancy turned out to be
associated with increased risk for diabetic nephropathy.
7.1 Limitations of the study
Several different methods and patient populations were employed in this series of studies. The
stiffness of the arteries was measured with applanation tonometry. This method has been shown to
be valid, and reproducible for the purpose. It enables measurement not only of the AIx but also the
PWV. Importantly, aortic PWV has recently been considered the “gold standard” of arterial
stiffness 212. Moreover, PWV is a predictor of cardiovascular disease 189. However, the PWV is
limited by the fact that it measures the elastic properties of a single arterial segment and not the
entire arterial system. Aix, in contrast, is a reproducible measure of generalized arterial stiffness,
but to avoid inaccuracy has to be corrected for heart rate 279.
Regarding number of patients, the study sample in Studies I to IV was large enough to reveal a
statistical significance between and within the studied groups. A power analysis was performed
prior to the study and showed that the chosen number of patients was sufficient.
It is of note that because supraphysiological levels of insulin reduce arterial stiffness 112, any effect
on the vasculature by hyperglycaemia could theoretically be mediated by a concomitant increase in
insulin. In these studies, the insulin excretion of the healthy volunteers was blocked by somatostatin
to control for any insulin effect. Moreover, other hormones that may also have affected results are
glucagon, catecholamines, cortisone, growth hormones, and prolactin. However, HR did not
increase during the clamp with regard to the catecholamines. Furthermore, a somatostatin analogue
can reduce arterial stiffness in patients with acromegaly 280. No studies regarding the effect of
glucagon, known to be elevated in patients with type 1 diabetes, were available.
Only males were studied to avoid any hormonal variations that might have had an effect on arterial
stiffness; results may therefore not be directly applicable to females. In addition, smokers, patients
with diabetic complications, or those using any medication other than insulin were excluded.
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Exclusion of these confounding factors made it possible, however, to explore independent effect of
the glucose metabolism on the vasculature.
Regarding Study V, a few limitations must be acknowledged. Firstly, microalbuminuria, not
measured quantitatively during pregnancy, could have been present in those patients with type 1
diabetes that did not progress to DN after pre-eclampsia. Proteinuria was, however, screened by the
dipstick test, and an albuminuria greater than 0.3 g during early pregnancy could thus be excluded.
The patients who had a positive dipstick test did in addition collect a 24 h urine sample to confirm
their albuminuria status. Secondly, approximately 50% of the patients studied during their
pregnancies did not attend the follow-up. It is noteworthy that these patients did not differ regarding
their baseline clinical characteristics from those who did participate (data not shown). Thirdly, data
from the time between the pregnancy and the follow-up visit were lacking; hence, a possibility
exists that the patients with pre-eclampsia may have had poor glycaemic control after pregnancy, a
fact that could have elevated their risk for diabetic nephropathy. This was, however, taken into
account in the analyses by adjusting for level of glycaemia. That the odds ratio in the logistic
regression analyses was as high as 7.7 after adjustment for glycaemia suggests that pre-eclampsia is
a true predictor of diabetic kidney disease in patients with type 1 diabetes.
7.2 Acute hyperglycaemia and arterial stiffness
Type 1 diabetes and arterial stiffness are important risk factors for cardiovascular disease. Study I
tested the hypothesis whether acute hyperglycaemia causes increased arterial stiffness and
demonstrated that acute hyperglycaemia does cause increased arterial stiffness measured by AIx
both in patients with type 1 diabetes and in healthy control subjects. These results confirm previous
data by Mullan et al. and also further extend the observation to patients with type 1 diabetes 8.
This  observation  is  also  consistent  with  earlier  findings  in  patients  with  type  2  diabetes  showing
depressed endothelial function during an oral glucose tolerance test 91. These investigations by
Kawano et al. were performed by measurement of flow-mediated endothelium-dependent
vasodilation by an ultrasound technique. Notably, endothelial dysfunction is a key component of
arterial stiffness, and thus these data from the Kawano group mirror the results seen in our study.
Furthermore, a study by Williams et al. also showed similar results in healthy subjects, although
they measured endothelial function by plethysmography 92. Taken together, these data suggest that
acute hyperglycaemia has a profound effect on the vasculature, and therefore it was not unexpected
that Capes et al. suggest a link between acute hyperglycaemia and a worse prognosis after
cardiovascular events, both in diabetic and non-diabetic patients 6. Interestingly, similar results have
also been reported after traumas in those non-diabetic 74.
Stiffness in intermediate-sized arteries (brachial PWV) in patients with type 1 diabetes increased,
whereas no corresponding response occurred in healthy subjects. In contrast, the stiffness of large
arteries (aortic PWV) did not change in response to acute hyperglycaemia in either group.
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Speculatively, the discrepancy might be due to differences in the structure of the aorta and the
brachial artery. The aortic walls consist mainly of elastin and collagen fibres, whereas the wall of
the brachial artery contains a considerable number of smooth muscle cells. This observation may
imply that chronic hyperglycaemia (diabetes) leads to increased reactivity to high glucose in small
and intermediate sized arteries.
We know from earlier studies that arterial stiffness measured by pulse pressure is higher in patients
with type 1 diabetes 228. A few studies have demonstrated that the AIx is significantly higher in
patients with type 1 diabetes than in healthy control subjects 199 203. However, smokers and patients
with hypertension and diabetic complications such as nephropathy were not excluded, a fact that
might explain the increased stiffness. In the present study, in a homogenous young group of patients
with type 1 diabetes and no complications, the presence of an increased arterial stiffness was
confirmed and registered as a difference in Aix, but the study did not reveal any differences in
either brachial or aortic PWV between diabetic and control subjects at baseline. Notably, these
results are to some extent consistent with those from McEniery et al. which indicates that AIx may
be a more sensitive marker of cardiovascular risk in younger individuals, whereas PWV may be a
better measure in older subjects 281.
7.3 Glucose variability and haemodynamic variables
The use of the continuous glucose monitoring system has opened a new line in research through
which  it  is possible to observe daily glucose variations in vivo. The measurements not only show
glucose concentration that can be monitored with conventional methods but also show
unpredictable glucose excursions. The most important characteristic of the CGMS is that it
recognizes intra-day glucose variability, a phenomenon that is less studied. The results of the
present study showed marked differences in glucose variability between patients (data not shown).
Study II showed that daily mean glucose concentration correlated with arterial stiffness but glucose
variability did not. This study was thus among the first to provide data regarding glucose variability
and surrogate markers for macrovascular disease in diabetes. Kilpatrick et al. 10 suggested that
glucose variability does not predict microvascular complications in patients with type 1 diabetes. In
another very recent paper, his group showed that daily mean blood glucose but not glucose
variability predicted macrovascular disease 10 11. Their results from the DCCT study were consistent
with those from our study, but elicited a lively debate, and further studies were requested 282 283.
Interestingly, daily glucose fluctuations have been suggested to be associated with oxidative stress
in  type  2  but  not  in  type  1  diabetes 166 167. Perhaps the postprandial hyperglycaemia in type 2
diabetes  is  actually  different  from  (and  more  atherogenic)  than  the  glucose  spikes  seen  in  type  1
diabetes. Further studies are certainly needed to gain additional information 284.
Although mean blood glucose was associated with aortic PWV in Study II, Study I did not show an
increase in aortic PWV in response to acute hyperglycaemia. These somewhat surprising results
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may be explained by the fact that Study I demonstrated the effects of short-term ( 2 hours)
hyperglycaemia, while Study II reflected mean blood glucose concentration over 3 days. This thesis
study cannot, however, provide a definite answer to this question.
The  findings  of  Study  II  may  support  the  role  of  hyperglycaemia  as  an  additional  risk  factor  for
macrovascular disease in patients with type 1 diabetes. The observations are also similar to those in
the DCCT/EDIC where strict glycaemic control reduced the progression of coronary artery
calcification, a surrogate marker of cardiovascular disease 62.  Orchard  et  al. 285 presented an
interesting “glucose stabilization” theory proposing that glycaemia relates more strongly to the
chronic stable atherosclerotic changes in peripheral arterial disease than to the unstable plaques in
coronary arteries. Interestingly, he also suggested that the stable plaques in the peripheral arteries
are related to the formation of AGEs 286.  In  general,  acute  coronary  events  occur  via  plaque
ruptures, and the plaques have been reported to be more vulnerable in patients with diabetes.
Another rather peculiar finding in this series was that patients with daily episodes of hypoglycaemia
had more elastic arteries and also a more anti-atherogenic lipid profile. It can be speculated that
these observations were due to better overall glycaemic control, an effect of the insulin or possibly
of more frequent physical activity in these patients 287 288.
Results from the hyperglycaemic clamp demonstrated that patients with type 1 diabetes and with
frequent daily glucose fluctuations had increased hyperglycaemia-induced haemodynamic
reactivity. These observations imply that the vasculature does not habituate to hyperglycaemia.
Rather,  the  opposite  relationship  was  apparent.  If  these  data  are  confirmed by  other  studies,  they
may have important clinical implications. SMBG should be intensively measured, regardless of
HbA1c concentration.
7.4 Acute hyperglycaemia and disturbed myocardial repolarisation
A prolonged QTc interval is a predictor of sudden death. Study III showed that acute
hyperglycaemia prolongs the QTc interval both in patients with type 1 diabetes and in healthy
volunteers. Cardiac arrest is, in fact, associated with QTc interval prolongation after an acute
myocardial infarction, and since acute hyperglycaemia has been demonstrated to induce
electrophysiological alterations in connection with an AMI, hyperglycaemia may be one of the
factors that lead to arrhythmias 75.
Children and adolescents with type 1 diabetes have higher mortality than do non-diabetic subjects
of  the  same  age 289. This observation originates from data linking these deaths to nocturnal
hypoglycaemia (“dead-in-bed” syndrome) 290. In this respect it is noteworthy that hypoglycaemia
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also prolongs the QTc in type 1 diabetes 291, suggesting that both hyper- and hypoglycaemia disturb
cardiac repolarisation.
Increased blood pressure, female sex, chronic hyperglycaemia (HbA1c), genetic suspectibility, and
ischaemic  heart  disease  have  been  risk  factors  for  QTc  prolongation.  In  patients  with  type  1
diabetes, autonomic neuropathy and diabetic nephropathy are associated with a prolonged QTc
interval 233. Considering Study III, it appears that in patients with type 1 diabetes not only chronic
but also acute hyperglycaemia is an additional risk factor for a prolonged QT interval 76. Whether
this explains the accentuated mortality in these patients during a cardiovascular event remains
unknown.
Clearly, no definite conclusions on the pathophysiological mechanisms can be drawn based on
Study III. It has been speculated that a prolonged QTc interval during hyperglycaemia may be due
to an elevated cytosolic calcium content in the myocytes and a lower threshold for ventricular
fibrillation and sudden death 292. Thus, an acutely elevated blood glucose concentration may result
in a decrease in the extracellular calcium concentration and an increase in the calcium influx into
the cells, and consequently in a prolonged QTc interval.
Interestingly, the changes in repolarisation during hyperglycaemia have been reversed by inhibition
of oxidative stress or of endothelial dysfunction in rats 238 239. Increased sympathetic activity in
response to acute hyperglycaemia is also possible 293,  although  Study  III  did  not  show  increased
heart rates during the clamp. Finally, disturbances in electrolyte balance may serve as an alternative
explanation, since not only hypokalemia but also hypocalcemia can cause QT-interval prolongation.
7.5 Inflammatory changes in the vasculature during acute hyperglycaemia
The main finding of Study IV was that acute hyperglycaemia caused a response in the inflammatory
markers both in young patients with type 1 diabetes without complications and in healthy age-
matched control subjects. A hyperglycaemia-induced rise in the marker of oxidative stress also
occurred.
To our knowledge, this may be is the first study to show an inflammatory response to acute
hyperglycaemia in patients with type 1 diabetes. These data are, however, in line with the
observations both from in vitro studies in monocytes and in vivo studies in non-diabetic subjects
that acute hyperglycaemia indeed induces an increase in  inflammatory cytokine concentrations 89
294. Moreover, the increase in superoxide dismutase, a marker of oxidative stress, is also consistent
with  similar  data  by  Marfella  et  al 101. Finally, thus far unpublished data from the same series
showed no increase in the cellular adhesion molecules ICAM and VCAM in response to acute
hyperglycaemia. This is of course not unexpected, since the half-life of these molecules is very
short, and a potential increase difficult to capture. We measured these molecules only at baseline
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and after 120 minutes of hyperglycaemia, so any short-term increase between these time-points
would have been missed.
Atherosclerosis is associated with chronic inflammation 82, and IL-6 and CRP are therefore not
unexpectedly elevated in patients with cardiovascular disease 295.  While  patients  with  type  1
diabetes have frequent episodes of hyperglycaemia as well as a substantially increased risk for
cardiovascular disease and other diabetic complications, it can be speculated that hyperglycaemia
(both chronic and acute) can induce inflammation (both chronic and acute), and this phenomenon
may even serve as an additional mechanism for long-term diabetic complications. This view is in
line with our previous data showing that patients with type 1 diabetes and diabetic nephropathy
have elevated CRP and IL-6 concentrations as a sign of chronic inflammation 126.
An interesting theory has been presented by Blake et al., proposing that an inflammatory process
disturbs the endothelial function of the arteries and thereby activates cellular adhesion molecules.
These in turn attract circulating leucocytes to migrate into the subendothelial space. Consequently,
macrophages express receptors for lipoproteins, forming lipid pools in the arteries. Furthermore,
endothelial cells as well as smooth muscle cells start to express inflammatory cytokines, e.g., TNF-
, IL-1, and IL-6, stimulating the liver to produce CRP. Eventually the immunomodulator CD40 is
expressed and mediates the expression of metalloproteinases; this disturbs the elastin/collagen
synthesis and breakdown balance, possibly resulting in increased arterial stiffness as well as in
thrombosis 296. Another hypothesis is that the inflammatory response to acute hyperglycaemia may
lead to ischaemia in the vessels of the arteries (vasa vasorum), and consequently to arterial
stiffening 297.
Chronic hyperglycaemia leads to oxidative stress, a phenomenon essential for the development of
diabetic complications. Acute hyperglycaemia also may cause oxidative stress in non-diabetic
subjects 101, an observation confirmed by Study IV. Antioxidants have in experimental studies
reduced the adverse effects of acute hyperglycaemia on endothelial function and inflammation 298.
Further studies are, however, needed to clarify the role of antioxidant therapy in the prevention of
cardiovascular disease.
7.6 Pre-eclampsia and diabetic nephropathy
The  most  important  finding  of  Study  V  was  that  women  with  both  type  1  diabetes  and  pre-
eclampsia during pregnancy were much more likely to develop diabetic nephropathy and high blood
pressure later in life than were women with type 1 diabetes and normal blood pressure during
pregnancy. Pregnancy-induced hypertension did not predispose to subsequent diabetic kidney
disease at follow-up, suggesting that these two entities (pre-eclampsia and pregnancy-induced
hypertension) truly represent different diseases.
59
A few studies have shown that pre-eclampsia predicts cardiovascular disease in the general
population 299.  Study  V  confirms  that  this  is  also  true  for  women  with  type  1  diabetes.  To  our
knowledge, only one study has explored the association between pre-eclampsia and microvascular
disease; it suggested that pre-eclampsia is associated with diabetic retinopathy 255.
Due to lack of a control group, Study V could not answer the question whether non-diabetic women
with pre-eclampsia also are at higher risk for kidney disease. However, in an earlier study from our
group, pre-eclamptic women without diabetes were followed for 5 years, and none of them showed
any signs of kidney disease at follow-up 300.
The mechanisms for these findings may relate to the endothelial dysfunction or low-grade
inflammation present both in nephropathy and pre-eclampsia 126 301 302 303. However, at the
morphological level, pre-eclampsia seems to be quite different from diabetic nephropathy. Pre-
eclampsia is more of a focal glomerulonephritis 304, while nephropathy is characterized as general
glomerulosclerosis 305. One could speculate that pre-eclampsia may be a trigger and thus cause an
insult to the kidney that predisposes to nephron loss and further to diabetic nephropathy in
susceptible individuals.
Interestingly, there may emerge a common genetic background for pre-eclampsia and diabetic
nephropathy, possibly through endothelial dysfunction, chronic inflammation, or insulin resistance
306. Another possibility is that pregnancy itself as a state of hypervolemia, acquired thrombophilia,
insulin resistance, and low-grade inflammation could induce pre-eclampsia as the first manifestation
of endothelial dysfunction in genetically susceptible individuals 307. Most likely several different
factors play roles in the relationship between these two diseases.
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7.7 Summary and conclusions
Acute hyperglycaemia was found to increase arterial stiffness in both males with type 1 diabetes
and in healthy age-matched non-diabetic male volunteers. A similar response to an acutely elevated
blood glucose concentration was observed in myocardial ventricular repolarisation, which was
prolonged in both groups. Inflammation and activation of oxidative stress also turned out to be
involved in the process. Notably, male patients with fluctuating daily blood glucose concentrations
showed an increased response to acute hyperglycaemia with respect to their central blood pressure.
On the other hand, a high mean daily blood glucose concentration was associated with increased
arterial stiffness, whereas HbA1c was not associated with arterial stiffness. Finally, women with
type 1 diabetes and pre-eclampsia during their pregnancy developed diabetic nephropathy more
often than did those with uncomplicated pregnancies. These findings underline the importance of
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